SAREPTA THERAPEUTICS INC
NASDAQ: SRPT (Sarepta Therapeutics, Inc.)
Last update: 11 hours ago20.11
-0.56 (-2.71%)
| Previous Close | 20.67 |
| Volume | 6,292,130 |
| Price / Earnings (Forward) | 20.88 |
| Price / Sales | 1.18 |
| Price / Book | 1.43 |
| 52 Weeks Range |
| Profit Margin | -11.12% |
| Operating Margin (TTM) | -40.33% |
| Diluted EPS (TTM) | -2.64 |
| Quarterly Revenue Growth (YOY) | 80.20% |
| Quarterly Earnings Growth (YOY) | 248.40% |
| Total Debt/Equity (MRQ) | 118.73% |
| Current Ratio (MRQ) | 4.02 |
| Operating Cash Flow (TTM) | -547.15 M |
| Levered Free Cash Flow (TTM) | -741.26 M |
| Return on Assets (TTM) | -2.19% |
| Return on Equity (TTM) | -23.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Sarepta Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.44 |
|
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.42% |
| % Held by Institutions | 96.33% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Erste Asset Management Gmbh | 30 Jun 2026 | 2,568,945 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |